AR045471A1 - Derivados de naftiridina sustituidos como inhibidores del factor inhibidor de la migracion de macrofagos y su uso en el tratamiento de enfermedades en el hombre - Google Patents
Derivados de naftiridina sustituidos como inhibidores del factor inhibidor de la migracion de macrofagos y su uso en el tratamiento de enfermedades en el hombreInfo
- Publication number
- AR045471A1 AR045471A1 ARP040102991A ARP040102991A AR045471A1 AR 045471 A1 AR045471 A1 AR 045471A1 AR P040102991 A ARP040102991 A AR P040102991A AR P040102991 A ARP040102991 A AR P040102991A AR 045471 A1 AR045471 A1 AR 045471A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- group
- nr4r5
- heterocycle
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Abstract
Se proveen inhibidores del factor inhibidor de la migración de macrófagos (MIF) con una estructura principal de naftiridina que son de utilidad en el tratamiento de una variedad de trastornos, incluyendo el tratamiento de afecciones patológicas asociadas con la actividad del MIF. Los inhibidores del MIF tienen las estructuras de las fórmulas (1), que incluyen estereoisómeros, prodrogas y sales aceptables para uso farmacéutico de los mismos. También se proveen composiciones que contienen un inhibidor de MIF en combinación con un vehículo aceptable para uso farmacéutico, así como métodos para utilizarlos. Reivindicación 1: Un compuesto donde, R se selecciona entre el grupo que consiste en hidrógeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, cicloalquilo, cicloalquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, acilalquilo, acilalquilo sustituido, heterociclo, heterociclo sustituido, -(CH2)mC(=O)Ar, y -(CH2)mNR4R5; R1 se selecciona entre el grupo que consiste en -CN, -NO, -NO2, -C(=O)R3, -C(=O)OH, -NHC(=O)R3, -C(=O)OR3, -C(=O)NR4R5, -NR3C(=O)R3, -SO2NR4R5, -NR3SO2R3, -NHSO2R3, -S(O)mR3, -(CH2)mNR4R5, y -(CH2)mC(=O)Ar; R2 se selecciona entre el grupo que consiste en - CH2R3, -NR4R5, -OR3, y -R3; R3 se selecciona independientemente entre el grupo que consiste en alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, cicloalquilo, cicloalquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, acilalquilo, acilalquilo sustituido, heterociclo, heterociclo sustituido; R4 y R5 se seleccionan independientemente entre el grupo que consiste en hidrógeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, cicloalquilo, cicloalquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, acilalquilo, acilalquilo sustituido, heterociclo, y heterociclo sustituido, o R4 y R5 tomados juntos comprenden heterociclo o heterociclo sustituido; X se selecciona entre el grupo que consiste en hidrógeno, halógeno, -F, -Cl, -CN, -NO, -NO2, -OCF3, -CF3, -NHSO2R3, -C(=O)R3, -C(=O)OR3, -C(=O)NR4R5, -NR3C(=O)R3, -NR3SO2R3, -S(O)mR3, -R3, -OR3, -SR3, -C(=O)OH, -NHC(=O)R3, y -NR4R5; Y se selecciona entre el grupo que consiste en hidrógeno, halógeno, -F, -Cl, -CN, -NO, -NO2, -OCF3, -CF3, -NHSO2R3, -C(=O)R3, -C(=O)OR3, -C(=O)NR4R5, -NR3C(=O)R3, -NR3SO2R3, -S(O)mR3, -R3, -OR3, -SR3, -C(=O)OH, -NHC(=O)R3, y -NR4R5; Z se selecciona entre el grupo que consiste en hidrógeno, halógeno, -F, -Cl, -CN, -NO, -NO2, -OCF3, -CF3, -NHSO2R3, -C(=O)R3, -C(=O)OR3, -C(=O)NR4R5, -NR3C(=O)R3, -NR3SO2R3, -S(O)mR3, -R3, -OR3, -SR3, -C(=O)OH, -NHC(=O)R3, y -NR4R5; Ar se selecciona entre el grupo que consiste en arilo y arilo sustituido; m es independientemente 0, 1, 2, 3 ó 4; y n es 0, 1 ó 2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49744303P | 2003-08-22 | 2003-08-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR045471A1 true AR045471A1 (es) | 2005-10-26 |
Family
ID=34272569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040102991A AR045471A1 (es) | 2003-08-22 | 2004-08-20 | Derivados de naftiridina sustituidos como inhibidores del factor inhibidor de la migracion de macrofagos y su uso en el tratamiento de enfermedades en el hombre |
Country Status (13)
Country | Link |
---|---|
US (2) | US20050124604A1 (es) |
EP (1) | EP1656376A1 (es) |
JP (1) | JP2007503388A (es) |
CN (1) | CN1839133A (es) |
AR (1) | AR045471A1 (es) |
AU (1) | AU2004268941A1 (es) |
BR (1) | BRPI0413695A (es) |
CA (1) | CA2531506A1 (es) |
MX (1) | MXJL06000006A (es) |
PE (1) | PE20051112A1 (es) |
TW (1) | TW200524928A (es) |
UY (1) | UY28483A1 (es) |
WO (1) | WO2005021546A1 (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY27304A1 (es) * | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
TW200418829A (en) * | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
CA2600175A1 (en) * | 2005-03-24 | 2006-03-20 | Avanir Pharmaceuticals | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors |
GB0605689D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
AU2007334323B2 (en) | 2006-12-18 | 2011-03-10 | Amgen Inc. | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
AU2007334321B2 (en) | 2006-12-18 | 2012-03-08 | Amgen Inc. | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
US7569726B2 (en) | 2007-04-18 | 2009-08-04 | Amgen Inc. | Indanone derivatives that inhibit prolyl hydroxylase |
ES2442847T3 (es) | 2007-04-18 | 2014-02-13 | Amgen, Inc | Quinolonas y azaquinolonas que inhiben la prolil hidroxilasa |
EP2150251B9 (en) | 2007-05-04 | 2013-02-27 | Amgen, Inc | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
EP2155746A2 (en) | 2007-05-04 | 2010-02-24 | Amgen, Inc | Diazaquinolones that inhibit prolyl hydroxylase activity |
US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
WO2011056566A2 (en) * | 2009-10-26 | 2011-05-12 | Sunesis Pharmaceuticals, Inc. | Compounds and methods for treatment of cancer |
US9050334B2 (en) | 2010-07-16 | 2015-06-09 | Innov88 Llc | MIF inhibitors and their uses |
JP5916730B2 (ja) * | 2010-09-06 | 2016-05-11 | グアンジョウ インスティテュート オブ バイオメディスン アンド ヘルス,チャイニーズ アカデミー オブ サイエンスィズ | アミド化合物 |
US9133164B2 (en) * | 2011-04-13 | 2015-09-15 | Innov88 Llc | MIF inhibitors and their uses |
CN103360388B (zh) * | 2012-04-10 | 2017-11-14 | 江苏先声药业有限公司 | 5‑氨基‑1,4‑二氢‑1,8‑萘啶衍生物及其药物组合物和用途 |
WO2015095052A1 (en) | 2013-12-17 | 2015-06-25 | Controlled Chemicals, Inc. | Isoindolin-1-ones as macrophage migration inhibitory factor (mif) inhibitors |
CR20190338A (es) | 2016-12-22 | 2019-09-09 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
ES2928576T3 (es) | 2017-09-08 | 2022-11-21 | Amgen Inc | Inhibidores de KRAS G12C y métodos de uso de los mismos |
CN107556309B (zh) * | 2017-09-11 | 2020-12-01 | 浙江永宁药业股份有限公司 | 多取代四氢萘啶类化合物的药物用途及其制备方法 |
AU2019262589B2 (en) | 2018-05-04 | 2022-07-07 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
US11045484B2 (en) | 2018-05-04 | 2021-06-29 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
EP3790886A1 (en) | 2018-05-10 | 2021-03-17 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
MA52765A (fr) | 2018-06-01 | 2021-04-14 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
WO2019241157A1 (en) * | 2018-06-11 | 2019-12-19 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
MX2020012261A (es) | 2018-06-12 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer. |
CA3104647A1 (en) * | 2018-06-27 | 2020-01-02 | Bristol-Myers Squibb Company | Naphthyridinone compounds useful as t cell activators |
WO2020006018A1 (en) * | 2018-06-27 | 2020-01-02 | Bristol-Myers Squibb Company | Substituted naphthyridinone compounds useful as t cell activators |
JP2020090482A (ja) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
AU2019384118A1 (en) | 2018-11-19 | 2021-05-27 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
CN111471059B (zh) * | 2019-01-23 | 2022-12-02 | 药捷安康(南京)科技股份有限公司 | Pde9抑制剂及其用途 |
EP3939588A4 (en) * | 2019-03-08 | 2023-01-11 | Transthera Sciences (Nanjing), Inc. | USES OF PHOSPHODIESTERASE INHIBITORS |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
SG11202112855WA (en) | 2019-05-21 | 2021-12-30 | Amgen Inc | Solid state forms |
AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
EP4225742A1 (en) | 2020-10-05 | 2023-08-16 | Enliven Therapeutics, Inc. | 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases |
WO2022093817A1 (en) * | 2020-10-26 | 2022-05-05 | Yale University | Macrophage migration inhibitory factor inhibitors, and methods of making and using same |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4324893A (en) * | 1979-04-18 | 1982-04-13 | American Home Products Corporation | 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
US4299814A (en) * | 1979-05-25 | 1981-11-10 | Monsanto Company | Radioimmunoassay of MIF |
US4284768A (en) * | 1980-07-02 | 1981-08-18 | American Home Products Corporation | 1,2-Dihydro-4-amino-2-oxo-3-quinoline-carboxylic acid derivatives |
ZW2485A1 (en) * | 1984-02-22 | 1986-09-24 | Wellcome Found | Cloning of dna for protozoal antigens |
US5733933A (en) * | 1984-03-19 | 1998-03-31 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
US5700447A (en) * | 1992-05-21 | 1997-12-23 | The Picowder Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
US5801200A (en) * | 1984-03-19 | 1998-09-01 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
US5869534A (en) * | 1992-05-21 | 1999-02-09 | The Picower Institute For Medical Research | Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom |
US5733524A (en) * | 1984-03-19 | 1998-03-31 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
AU592753B2 (en) | 1984-05-24 | 1990-01-25 | Ciba-Geigy Ag | Lymphokine in pure foem, novel monoclonal antibodies hybridoma cell lines, processes and applications |
US4708937A (en) * | 1984-10-15 | 1987-11-24 | Brigham & Women's Hospital | Purified migration inhibitory factor also having colony stimulating factor activity |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
GB8602626D0 (en) * | 1986-02-04 | 1986-03-12 | Ciba Geigy Ag | Neurite-promoting factor |
EP0263072B1 (en) | 1986-10-03 | 1994-03-23 | Ciba-Geigy Ag | Novel lymphokine related peptides |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
FI82144C (fi) * | 1989-03-22 | 1991-01-10 | Wallac Oy | Foerfarande foer samtidig bestaemning av flera ligander. |
GB8915414D0 (en) | 1989-07-05 | 1989-08-23 | Ciba Geigy | Novel cytokines |
US5328990A (en) * | 1991-04-26 | 1994-07-12 | The United States Of America As Represented By The Department Of Health And Human Services | Isolation of macrophage migration inhibition factor from ocular lens |
CA2054602C (en) * | 1991-10-31 | 2003-04-22 | Anthony Pawson | Method for assaying for a substance that affects an sh2-phosphorylated ligand regulatory system |
US5624804A (en) * | 1991-12-20 | 1997-04-29 | The Rockefeller University | Immunochemical detection of In vivo advanced glycosylation end products |
JP4708510B2 (ja) | 1993-05-17 | 2011-06-22 | サイトカイン ファーマサイエンシズ,インコーポレーテッド | サイトカイン媒介毒性に関係する疾患の治療における遊走阻止因子の抑制 |
US6774227B1 (en) | 1993-05-17 | 2004-08-10 | Cytokine Pharmasciences, Inc. | Therapeutic uses of factors which inhibit or neutralize MIF activity |
US6030615A (en) * | 1993-05-17 | 2000-02-29 | The Picower Institute For Medical Research | Combination method for treating diseases caused by cytokine-mediated toxicity |
US5650295A (en) * | 1995-06-02 | 1997-07-22 | Human Genone Sciences, Inc. | Macrophage migration inhibitory factor-3 |
US6492428B1 (en) | 2000-07-26 | 2002-12-10 | The Picower Institute For Medical Research | Compounds having MIF antagonist activity |
US6420188B1 (en) * | 1996-02-16 | 2002-07-16 | The Picower Institute For Medical Research | Screening assay for the identification of inhibitors for macrophage migration inhibitory factor |
JP2000512737A (ja) | 1996-04-18 | 2000-09-26 | アリアッド ファーマスーティカルズ,インク. | 試験管内蛍光偏光検定法 |
US5883224A (en) | 1996-04-19 | 1999-03-16 | Cytokine Sciences, Inc. | Characterization of transfer factors and methods of use |
JPH1171351A (ja) | 1997-08-29 | 1999-03-16 | Ss Pharmaceut Co Ltd | 置換キノロン誘導体及びこれを含有する医薬 |
US6413939B1 (en) * | 1997-10-31 | 2002-07-02 | The Picower Institute For Medical Research | Inducible phosphofructokinase and the Warburg effect |
DK1036192T3 (da) | 1997-12-05 | 2003-06-10 | Upjohn Co | Fluorescensbaserede screeningsanalyser med høj hastighedforproteinkinaser og phosphataser |
EP1101106A4 (en) * | 1998-07-28 | 2006-05-03 | Bd Biosciences Systems And Rea | DEVICE AND METHOD FOR ANALYZING CELLULAR MOTILITY |
US6214343B1 (en) * | 1999-05-24 | 2001-04-10 | Ophidian Pharmaceuticals, Inc. | Prevention and treatment of necrotizing enterocolitis |
WO2001028993A2 (en) * | 1999-10-19 | 2001-04-26 | Merck & Co. Inc. | Tyrosine kinase inhibitors |
CA2389229A1 (en) * | 1999-10-29 | 2001-05-10 | The Picower Institute For Medical Research | Compounds having mif antagonist activity |
CA2431904A1 (en) * | 2000-12-20 | 2002-08-01 | Merck & Co., Inc. | (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
UY27304A1 (es) * | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
JP4117462B2 (ja) * | 2001-07-03 | 2008-07-16 | 株式会社大塚製薬工場 | ナフチリジンおよびキノリン誘導体 |
US6822097B1 (en) * | 2002-02-07 | 2004-11-23 | Amgen, Inc. | Compounds and methods of uses |
JP2006511445A (ja) * | 2002-06-07 | 2006-04-06 | コーティカル・ピーティーワイ・リミテッド | マクロファージ遊走阻止因子(mif)のサイトカインまたは生物学的活性を阻害するナフタレン誘導体 |
TW200418829A (en) * | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
-
2004
- 2004-08-09 CA CA002531506A patent/CA2531506A1/en not_active Abandoned
- 2004-08-09 MX MXJL06000006A patent/MXJL06000006A/es unknown
- 2004-08-09 JP JP2006523903A patent/JP2007503388A/ja active Pending
- 2004-08-09 CN CNA2004800241375A patent/CN1839133A/zh active Pending
- 2004-08-09 BR BRPI0413695-0A patent/BRPI0413695A/pt not_active IP Right Cessation
- 2004-08-09 WO PCT/US2004/025683 patent/WO2005021546A1/en active Application Filing
- 2004-08-09 EP EP04780510A patent/EP1656376A1/en not_active Ceased
- 2004-08-09 AU AU2004268941A patent/AU2004268941A1/en not_active Abandoned
- 2004-08-17 US US10/920,031 patent/US20050124604A1/en not_active Abandoned
- 2004-08-18 TW TW093124762A patent/TW200524928A/zh unknown
- 2004-08-20 AR ARP040102991A patent/AR045471A1/es not_active Application Discontinuation
- 2004-08-20 UY UY28483A patent/UY28483A1/es not_active Application Discontinuation
- 2004-08-21 PE PE2004000808A patent/PE20051112A1/es not_active Application Discontinuation
-
2007
- 2007-03-16 US US11/687,601 patent/US7361760B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
BRPI0413695A (pt) | 2006-10-24 |
AU2004268941A1 (en) | 2005-03-10 |
US20050124604A1 (en) | 2005-06-09 |
UY28483A1 (es) | 2005-03-31 |
CA2531506A1 (en) | 2005-03-10 |
WO2005021546A1 (en) | 2005-03-10 |
CN1839133A (zh) | 2006-09-27 |
MXJL06000006A (es) | 2006-05-04 |
US7361760B2 (en) | 2008-04-22 |
EP1656376A1 (en) | 2006-05-17 |
JP2007503388A (ja) | 2007-02-22 |
TW200524928A (en) | 2005-08-01 |
US20070191388A1 (en) | 2007-08-16 |
PE20051112A1 (es) | 2006-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR045471A1 (es) | Derivados de naftiridina sustituidos como inhibidores del factor inhibidor de la migracion de macrofagos y su uso en el tratamiento de enfermedades en el hombre | |
AR036032A1 (es) | Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif | |
AR043190A1 (es) | Derivados de quinoleina como inhibidores del factor inhibidor de la migracion de macrofagos y metodos para su identificacion. sintesis y composiciones farmaceuticas. | |
AR043199A1 (es) | Componentes heterociclicos utiles para el tratamiento de enfermedades inflamatorias y alergicas, proceso para su operacion y composicion farmaceutica que contiene dichos componentes | |
AR046736A1 (es) | Derivados organofosforados de los indazoles y su utilizacion como medicamentos con actividad anticancerosa. | |
AR073701A1 (es) | Derivados de indol y de indolicina, metodos para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades neurodegenerativas. | |
GT200500242A (es) | Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas | |
AR036044A1 (es) | Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma | |
AR004180A1 (es) | Nuevos derivados de pirimidona con actividad antifungica y procedimiento para preparar los mismos. | |
ECSP099496A (es) | Compuestos inhibidores de fosfofinosítido 3-quinasas y métodos de uso | |
AR047531A1 (es) | Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa | |
ECSP056127A (es) | Inhibidores de 3-quinasa de fosfatidil-inositol | |
RU2011124304A (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
DOP2005000076A (es) | "compuestos de aril-o heteroarilamida ortosustituidos" | |
AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
AR035234A1 (es) | Aril y biaril-piperidinas con actividad moduladora mch, metodo para preparar dichos compuestos, composiciones farmaceuticas, metodo para preparar las composiciones farmaceuticas y el uso de dichos compuestos para la manufactura de un medicamento | |
PE20060583A1 (es) | Tiazolil-dihidro-indazoles como inhibidores de pi3-quinasas | |
ECSP034642A (es) | Derivados de tetralona como agentes antitumorales | |
ECSP066968A (es) | Compuestos de metil-aril o heteroaril-amida sustituida | |
ECSP10010507A (es) | Pirazolo (3, 4-b) piridina inhibidores de raf | |
AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
AR052269A1 (es) | Analogos de rapamicina, un proceso para su elaboracion y los usos de los mismos en la preparacion de un medicamento para el tratamiento de trastornos neurologicos, proliferativos e inflamatorios. | |
ES2266459T3 (es) | Uso de compuestos de azetidinona sustituidos para el tratamiento de sitosterolemia. | |
DOP2003000694A (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
UA90483C2 (uk) | Похідні n-(1н-індоліл)-1н-індол-2-карбоксамідів, їх отримання і їх застосування в терапії |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |